Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4277-4287

  Carpenter, Erica L ^a   Mick, Rosemarie ^a,b   Rech, Andrew J ^a   Beatty, Gregory L ^a,b   Colligon, Theresa A ^a   Rosenfeld, Myrna R ^a,b   Kaplan, David E ^b   Chang, Kyong Mi ^a,b   Domchek, Susan M ^a,b   Kanetsky, Peter A ^a,b   Fecher, Leslie A ^a,b   Flaherty, Keith T ^a,b   Schuchter, Lynn M ^a,b   Vonderheide, Robert H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ADULT; ADVANCED CANCER; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY CELL; MIXED LYMPHOCYTE CULTURE; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PLASMACYTOSIS; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADULT; ANTIGENS, CD27; APOPTOSIS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MELANOMA; NEOPLASMS; PLASMA CELLS; TRANSPLANTATION, HOMOLOGOUS; TUMOR ESCAPE;

EID: 67650381830     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0537     Document Type: Article

References (49)

1. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008;122:12 - 9.
2. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW,TedderTF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008;223: 284 - 99.
3. De Milito A, Morch C, Sonnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1infection. AIDS 2001;15:957-64.
4. Titanji K, De Milito A, Cagigi A, et al. Loss ofmemory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006;108: 1580 - 7.
5. Malaspina A, Moir S, Chaitt DG, et al. Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 2007;109:2086 - 8.
6. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B-cell compartment in HIV-infected viremic individuals. J Exp Med 2008;205:1797-805.
7. Malaspina A,Moir S, Kottilil S, et al. Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. JImmunol 2003;170:5965-72.
8. Moir S, Malaspina A, Pickeral OK, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of theTNF superfamily. JExpMed 2004;200:587-99.
9. Moir S, Malaspina A, Ho J, et al.Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. JInfectDis 2008;197:572-9.
10. Ni J, Hembrador E, Di Bisceglie AM, et al. Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol 2003;170:3429-39.
11. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9.
12. Chang NH, McKenzie T, Bonventi G, et al. Expanded population of activated antigen-engaged cells within the naive B-cell compartment of patientswith systemic lupus erythematosus. J Immunol 2008;180:1276-84.
13. Wei C, Anolik J,Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007;178: 6624 - 33.
14. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007;13:5256-61.
15. Zippelius A, Gati A, Bartnick T, et al. Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunol Immunother 2007;56: 249 - 58.
16. Al-Batran SE, Rafiyan MR, Atmaca A, et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005; 65:3937-41.
17. Staquicini FI, Tandle A, Libutti SK, et al. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res 2008;68:8419 - 28.
18. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxicT lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319-3325.
19. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigen are effective antigen-presenting cells that can generate specific T cells. Can Res 2003;63:2836-43.
20. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004;103:2046-54.
21. Coughlin CM, Fleming MD, Carroll RG, et al. Immunosurveillance and survivin-specificT-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006;24:5725-34.
22. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity.NatMed1998;4:627-30.
23. Perricone MA, Smith KA, Claussen KA, et al. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 2004;27:273-281.
24. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL andTH1cytokine responses by B cells. Int JCancer 2005;117:574 - 86.
25. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006;66:7741-7.
26. Kim S, Fridlender ZG, Dunn R, et al. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother 2008;31: 446-57.
27. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008;224:201-14.
28. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7: 411 - 23.
29. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25:876-83.
30. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc B1995;57:289-300.
31. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998;188:1679-89.
32. Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002;100:1113 -22.
33. Odendahl M, Mei H, Hoyer BF, et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005;105:1614 - 21.
34. Weller S, Braun MC,Tan BK, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004;104:3647-54.
35. Amu S, Tarkowski A, Dorner T, Bokarewa M, Brisslert M. The human immunomodulatory CD25+ B-cell population belongs to the memory B cell pool. Scand J Immunol 2007;66:77-86.
36. van Kooten C, Banchereau J. CD40-40 ligand. JLeukoc Biol 2000;67:2-17.
37. Wagner M, Poeck H, Jahrsdoerfer B, et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 2004;172:954-63.
38. Malaspina A, Moir S, DiPoto AC, et al. CpG oligonucleotides enhance proliferative and effector responses of B Cells in HIV-infected individuals. J Immunol 2008;181:1199-206.
39. Buhlmann JE, Foy TM, Aruffo A, et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995;2:645-53.
40. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science1992;258:1156-1159.
41. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A1992;89:1890-3.
42. Kruger-Krasagakes S, Krasagakis K, Garbe C, et al. Expression of interleukin 10 in human melanoma. Br J Cancer1994;70:1182-5.
43. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 2000;83: 847-52.
44. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005;105: 4390-8.
45. Fecteau JF, Cote G, Neron S. A new memory CD27-IgG+ B-cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. J Immunol 2006;177:3728-36.
46. Duty JA, Szodoray P, Zheng NY, et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009;206:139-51.
47. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82.
48. Deola S, Panelli MC, Maric D, et al. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/ CD70 interactions. J Immunol 2008;180:1362-72.
49. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance inmetastatic melanoma. Int JCancer 1997;73:309-16.